Sinopharm Holdings, a joint venture between China National Pharmaceutical Group and Fosun International, is making progress on its planned $1 billion IPO in Hong Kong. The company announced it has found eight “cornerstone” investors who will together buy 20% of the offering. In exchange for a guaranteed number of shares, the investors pledged to hold their shares for an unspecified period. More details...

Stock Symbol: (SHA: 600511) (HK: 0656)